Dr. Yes Tag Wart Remover

Description

Salicylic acid is the active ingredient in this formulation, comprising 40% of the product. The product is presented as a topical solution, designed for application to the skin.

Uses and Indications

This drug is indicated for the removal of warts and corns.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly. Soaking the wart in warm water for 5 minutes is optional but may enhance the effectiveness of the treatment. After washing, the area must be dried completely.

If necessary, the medicated plaster can be cut to fit the size of the wart. The plaster should then be applied directly to the wart.

This application should be repeated every 48 hours as needed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated, infected, or reddened skin is prohibited due to the potential for exacerbating these conditions. The product should not be applied to genital warts, facial warts, moles, birthmarks, or warts with hair growing from them, as these areas may be sensitive and could lead to adverse reactions. Additionally, application on mucous membranes is contraindicated to prevent irritation and potential complications.

Contact with the eyes or face should be strictly avoided. In the event of accidental exposure to the eyes, it is essential to rinse thoroughly with water to mitigate any potential harm.

Warnings and Precautions

For external use only. This product is not intended for ingestion. In the event of accidental swallowing, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay.

Healthcare professionals should advise patients to discontinue use and consult a physician if discomfort persists. Monitoring for any adverse reactions is essential to ensure patient safety and effective management of any potential side effects.

No specific laboratory tests are recommended for the safe use of this product. However, vigilance in monitoring patient responses is advised to facilitate timely intervention if necessary.

Side Effects

For external use only. Patients should discontinue use if discomfort persists. It is advised that individuals with diabetes or poor blood circulation consult a doctor prior to use.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Dr. Yes Tag Wart Remover (salicylic acid 40% tag wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep the medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no information available regarding the use of DR.YES TAG WART REMOVER (salicylic acid 40% tag wart remover patch) during pregnancy. The drug insert does not provide safety concerns, dosage modifications, or special precautions for pregnant patients. Therefore, healthcare professionals should exercise caution when considering the use of this product in women who are pregnant or may become pregnant, as the potential risks to fetal outcomes are not established. It is advisable to weigh the benefits against any unknown risks before recommending this treatment to pregnant patients.

Lactation

There are no specific warnings or recommendations regarding the use of this product in lactating mothers. Additionally, there are no statements concerning the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage for this product (SPL code 34088-5), healthcare professionals are advised to exercise caution and consider general principles of management for suspected overdosage situations.

Recommended Actions In the event of an overdosage, it is essential to assess the patient's clinical status promptly. Healthcare providers should initiate supportive care and monitor vital signs closely. Depending on the severity of symptoms, further interventions may be necessary.

Potential Symptoms While specific symptoms related to overdosage are not detailed, healthcare professionals should remain vigilant for any unusual or severe reactions that may arise. Symptoms may vary based on the pharmacological profile of the substance involved.

Management Procedures Management of overdosage should be tailored to the individual patient and may include symptomatic treatment and supportive measures. In cases where the substance is known to have antidotes or specific treatment protocols, these should be implemented as appropriate. Consultation with a poison control center or toxicology expert is recommended for guidance on managing overdosage effectively.

In summary, due to the lack of specific overdosage information, healthcare professionals should rely on established protocols for managing suspected overdosage and remain alert to the potential for adverse effects.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Patients should be advised to seek medical help or contact a Poison Control Center immediately if the product is swallowed. It is important to inform patients that the product should not be applied to irritated, infected, or reddened skin, as well as on genital warts, warts on the face, moles, birthmarks, or warts with hair growing from them, and on mucous membranes.

Healthcare providers should counsel patients to monitor for any persistent discomfort following the use of the product. Instruct patients to avoid contact with the eyes or face, and if the product inadvertently gets into the eyes, they should rinse thoroughly with water.

Additionally, patients should be encouraged to consult their healthcare provider if they have diabetes or poor blood circulation before using the product.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within the temperature range of 59°F to 86°F (15°C to 30°C) to maintain its efficacy and integrity. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable container that protects it from environmental factors. Special handling requirements should be observed to prevent any compromise to the product's quality.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Dr. Yes Tag Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)